<VariationArchive VariationID="495685" VariationName="NM_000156.6(GAMT):c.491dup (p.Val165fs)" VariationType="Duplication" Accession="VCV000495685" Version="15" RecordType="classified" NumberOfSubmissions="7" NumberOfSubmitters="7" DateLastUpdated="2024-06-23" DateCreated="2018-03-17" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="488043" VariationID="495685">
      <GeneList>
        <Gene Symbol="GAMT" FullName="guanidinoacetate N-methyltransferase" GeneID="2593" HGNC_ID="HGNC:4136" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1397026" stop="1401542" display_start="1397026" display_stop="1401542" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1397024" stop="1401568" display_start="1397024" display_stop="1401568" Strand="-" />
          </Location>
          <OMIM>601240</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000156.6(GAMT):c.491dup (p.Val165fs)</Name>
      <CanonicalSPDI>NC_000019.10:1398994:CCCCCC:CCCCCCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>19p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1398994" stop="1398995" display_start="1398994" display_stop="1398995" variantLength="1" positionVCF="1398994" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1398993" stop="1398994" display_start="1398993" display_stop="1398994" variantLength="1" positionVCF="1398993" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <OtherNameList>
        <Name>NM_000156.6(GAMT):c.491dup</Name>
        <Name>p.Val165fs</Name>
      </OtherNameList>
      <ProteinChange>V165fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.1399000dup" Assembly="GRCh38">
            <Expression>NC_000019.10:g.1399000dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.1398999dup" Assembly="GRCh37">
            <Expression>NC_000019.9:g.1398999dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009785.1" sequenceAccession="NG_009785" sequenceVersion="1" change="g.7559dup">
            <Expression>NG_009785.1:g.7559dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.6" sequenceAccession="NM_000156" sequenceVersion="6" change="c.491dup" MANESelect="true">
            <Expression>NM_000156.6:c.491dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000147.1" sequenceAccession="NP_000147" sequenceVersion="1" change="p.Val165fs">
            <Expression>NP_000147.1:p.Val165fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_138924.3" sequenceAccession="NM_138924" sequenceVersion="3" change="c.491dup">
            <Expression>NM_138924.3:c.491dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_620279.1" sequenceAccession="NP_620279" sequenceVersion="1" change="p.Val165fs">
            <Expression>NP_620279.1:p.Val165fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA9043628" DB="ClinGen" />
        <XRef Type="rs" ID="749390953" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000156.6(GAMT):c.491dup (p.Val165fs) AND Deficiency of guanidinoacetate methyltransferase" Accession="RCV000587091" Version="9">
        <ClassifiedConditionList TraitSetID="2278">
          <ClassifiedCondition DB="MedGen" ID="C0574080">Deficiency of guanidinoacetate methyltransferase</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2022-06-06" SubmissionCount="5">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000156.6(GAMT):c.491dup (p.Val165fs) AND Cerebral creatine deficiency syndrome" Accession="RCV001382861" Version="8">
        <ClassifiedConditionList TraitSetID="16862">
          <ClassifiedCondition DB="MedGen" ID="C5244016">Cerebral creatine deficiency syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-10-23" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-06" NumberOfSubmissions="7" NumberOfSubmitters="7" DateCreated="2018-03-17" MostRecentSubmission="2024-06-17">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11136556</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11978605</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12557293</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15108290</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28438604</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/fdce6280-2ceb-4082-aa3b-48db0b1651f7</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="2278" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2252" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CEREBRAL CREATINE DEFICIENCY SYNDROME 2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0005" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Deficiency of guanidinoacetate methyltransferase</ElementValue>
                <XRef ID="Guanidinoacetate+Methyltransferase+Deficiency/3202" DB="Genetic Alliance" />
                <XRef ID="124239003" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCDS2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2578" />
                <XRef ID="2578" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Guanidinoacetate, Guanidinoacetate Methyltransferase Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Algorithm, GAMT Deficiency: Elevated Guanidinoacetate, 2022</CitationText>
              </Citation>
              <XRef ID="382" DB="Orphanet" />
              <XRef ID="C0574080" DB="MedGen" />
              <XRef ID="MONDO:0012999" DB="MONDO" />
              <XRef Type="MIM" ID="612736" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="16862" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="16661" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Creatine deficiency syndromes</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Cerebral creatine deficiency syndrome</ElementValue>
                <XRef ID="MONDO:0000456" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCAD</ElementValue>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CDS</ElementValue>
                <XRef ID="79172" DB="Orphanet" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18952" />
                <XRef ID="18952" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <XRef ID="79172" DB="Orphanet" />
              <XRef ID="C5244016" DB="MedGen" />
              <XRef ID="MONDO:0000456" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1362064" SubmissionDate="2018-01-25" DateLastUpdated="2018-03-17" DateCreated="2018-03-17">
        <ClinVarSubmissionID localKey="NM_000156.4:c.491dupG|MedGen:C0574080" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000695712" DateUpdated="2018-03-17" DateCreated="2018-03-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12557293</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15108290</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11978605</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11136556</ID>
          </Citation>
          <Comment>Variant summary: The GAMT c.491dupG (p.Val165Argfs) variant results in a premature termination codon, predicted to cause a truncated or absent GAMT protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One in silico tool predicts a damaging outcome for this variant. This variant was found in 3/120398 control chromosomes at a frequency of 0.0000249, which does not exceed the estimated maximal expected allele frequency of a pathogenic GAMT variant (0.001118). This variant has been reported in GAMTD patients both as homozygote and compound heterozygote. In addition, the GAMT activity in lymphoblasts was less than 10% of lower limit of controls (schulze_AN_2003). Taken together, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
            <CitationText>LabCorp Variant Classification Summary - May 2015.docx</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="768985121" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.4:c.491dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0574080" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016-2017-variants</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3896951" SubmissionDate="2021-11-02" DateLastUpdated="2022-02-02" DateCreated="2021-11-05">
        <ClinVarSubmissionID localKey="bd4c2d08-50f5-4d95-af71-6f3533fe61a4" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001999912" DateUpdated="2022-02-02" DateCreated="2021-11-05" Type="SCV" Version="2" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The p.Val165fs variant in GAMT has been reported in 3 individuals with cerebral creatine deficiency syndrome (PMID: 11136556, 12557293, 28438604), and has been identified in in 0.01% (2/19944) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs768985121). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of the 3 affected individuals, 1 of those was a homozygote and 2 were compound heterozygotes that carried variants of uncertain significance in trans, which increases the likelihood that the p.Val165fs variant is pathogenic (Variation ID: 939221; PMID: 11136556, 12557293, 28438604). This variant has also been reported in ClinVar (Variation ID#: 495685) and has been interpreted as pathogenic by Integrated Genetics (Laboratory Corporation of America) and Invitae. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 165 and leads to a premature termination codon 26 amino acids downstream. This termination codon occurs within the terminal 50 bases of the penultimate exon and is more likely to escape nonsense mediated decay (NMD) and result in a truncated protein. Loss of function of the GAMT gene is an established disease mechanism in autosomal recessive cerebral creatine deficiency syndrome. The phenotype of individuals homozygous or compound heterozygous for this variant is highly specific for cerebral creatine deficiency syndrome based on strict biochemical investigations consistent with disease (PMID: 11136556, 12557293, 28438604). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive cerebral creatine deficiency syndrome. ACMG/AMP Criteria applied: PVS1_strong, PM3, PP4_strong, PM2_supporting (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Abbrev="ACMG, 2015" Type="practice guideline">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000156.6(GAMT):c.491dup</Name>
            <Name>p.Val165fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.10:g.1399000dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0000456" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10607670</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4077433" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000156.6:c.491dup|Guanidinoacetate methyltransferase deficiency" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002087024" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-08-07">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.491dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Guanidinoacetate methyltransferase deficiency</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="5080856" SubmissionDate="2022-11-09" DateLastUpdated="2022-11-13" DateCreated="2022-11-13">
        <ClinVarSubmissionID localKey="fdce6280-2ceb-4082-aa3b-48db0b1651f7" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002600145" DateUpdated="2022-11-13" DateCreated="2022-11-13" Type="SCV" Version="1" SubmitterName="ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen" OrgID="508816" OrganizationCategory="consortium" OrgAbbreviation="ClinGen CCDS VCEP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-06">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/fdce6280-2ceb-4082-aa3b-48db0b1651f7</URL>
          </Citation>
          <Comment>The NM_000156.6:c.491dup (p.Val165ArgfsTer26) variant in GAMT is a frameshift variant predicted to cause a premature stop codon in the last 50 nucleotides of the penultimate exon of the gene and therefore to escape nonsense mediated decay. More than 10% of the protein is predicted to be removed (PVS1_Strong; PMID: 11136556). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001 in the East Asian population, which is less than the ClinGen CCDS VCEP's threshold (&lt;0.0004) (PM2_Supporting). The variant was found in homozygosity in one patient who meets the ClinGen CCDS VCEP's PP4 specifications (PMID 12557293). This variant was also found in compound heterozygosity in two patients who meet ClinGen CCDS VCEP’s PP4 specifications; one with the variant c.564G&gt;T (p. Met188Ile) (PMID 28438604) or "IVS5-3C&gt;G" (PMID 11136556). However, the in trans data from these two patients will be used in the assessment of the second variant and is not included here to avoid circular logic. (PM3_Supporting). Three patients have been reported with this variant and clinical and biochemical features consistent with GAMT deficiency including an adult patient with low creatine and elevated GAA in urine, plasma, and CSF, &lt;10% normal GAMT activity in fibroblasts, and absent creatine peak with GAA detected on MRS (PMID 12557293), low creatine and elevated GAA in plasma and urine and absent creatine peak on MRS (PMID 28438604), and elevated GAA in plasma, urine, and CSF, and lacking creatine peak on brain MRS (PMID 1136556)(PP4_Strong). There is a ClinVar entry for this variant (Variation ID: 495685) In summary, this variant meets the criteria to be classified as Pathogenic for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PVS1_Strong, PP4_Strong, PM2_Supporting, PM3_Supporting. (Classification approved by the ClinGen CCDS VCEP on June 6, 2022).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen_CCDS_ACMG_Specifications_GAMT_v1.1</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8u1i2ttx/clingen_ccds_acmg_specifications_gamt_v1.1.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000156.6(GAMT):c.491dup</Name>
            <Name>p.Val165fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.10:g.1399000dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0012999" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12271376</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7113471" SubmissionDate="2023-03-01" DateLastUpdated="2023-03-04" DateCreated="2023-03-04">
        <ClinVarSubmissionID localKey="ee14f09d239be23782d77cfe53b1e8ed" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003807372" DateUpdated="2023-03-04" DateCreated="2023-03-04" Type="SCV" Version="1" SubmitterName="Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein" OrgID="508506" OrganizationCategory="laboratory" OrgAbbreviation="LABO-HIAE" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>ACMG classification criteria: PVS1 very strong, PS4 moderated, PM2 moderated, PM3 moderated</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Brazil</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <Description>Paired-end whole-genome sequencing</Description>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0000252" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0012758" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001166" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0008551" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0004322" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.491dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612736" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12925816</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3107431" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="4345986|MedGen:CN227588" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001581811" DateUpdated="2024-02-14" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11136556</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12557293</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28438604</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Val165Argfs*26) in the GAMT gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 72 amino acid(s) of the GAMT protein. This variant is present in population databases (rs768985121, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with cerebral creatine deficiency syndrome (PMID: 11136556, 12557293, 28438604). ClinVar contains an entry for this variant (Variation ID: 495685). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.1398993_1398994insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN227588" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7846338" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000156.6:c.491dup|OMIM:612736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004198583" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.491dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612736" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7113471" TraitType="Disease" MappingType="XRef" MappingValue="612736" MappingRef="OMIM">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113471" TraitType="Finding" MappingType="XRef" MappingValue="HP:0000252" MappingRef="HP">
        <MedGen CUI="C4551563" Name="Microcephaly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113471" TraitType="Finding" MappingType="XRef" MappingValue="HP:0012758" MappingRef="HP">
        <MedGen CUI="C4022738" Name="Neurodevelopmental delay" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3107431" TraitType="Disease" MappingType="XRef" MappingValue="CN227588" MappingRef="MedGen">
        <MedGen CUI="C5244016" Name="Cerebral creatine deficiency syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113471" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001166" MappingRef="HP">
        <MedGen CUI="C0003706" Name="Arachnodactyly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113471" TraitType="Finding" MappingType="XRef" MappingValue="HP:0008551" MappingRef="HP">
        <MedGen CUI="C0152423" Name="Microtia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5080856" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0012999" MappingRef="MONDO">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3896951" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0000456" MappingRef="MONDO">
        <MedGen CUI="C5244016" Name="Cerebral creatine deficiency syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1362064" TraitType="Disease" MappingType="XRef" MappingValue="C0574080" MappingRef="MedGen">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4077433" TraitType="Disease" MappingType="Name" MappingValue="Guanidinoacetate methyltransferase deficiency" MappingRef="Preferred">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7846338" TraitType="Disease" MappingType="XRef" MappingValue="612736" MappingRef="OMIM">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113471" TraitType="Finding" MappingType="XRef" MappingValue="HP:0004322" MappingRef="HP">
        <MedGen CUI="C0349588" Name="Short stature" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2023-03-03">SCV002024176</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

